Status:
UNKNOWN
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Conditions:
CMV Infection
Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
Detailed Description
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used as the sole curative treatment for malignant hematological diseases. However, the chances of contracting various pathogeni...
Eligibility Criteria
Inclusion
- HSCT candidate who has decided to primary transplant and is willing to participate in the study.
- HSCT candidate undergo mNGS detection before transplantation.
Exclusion
- Patients below 14 years ago or above 65 years ago.
- Patients having active infection at the time of letermovir initiation.
- Patient recruited in a clinical study on an anti-CMV trial, or took similar anti-CMV drugs previously.
Key Trial Info
Start Date :
July 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06021210
Start Date
July 7 2022
End Date
September 1 2025
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006